Therapy Detail

Therapy Name NMS-P088
Synonym
Therapy Description

NMS-P088 inhibits Flt3, Kit, and Csf1r, thus may have anti-tumor activity in hematological cancers (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
NMS-P088 NMS-P088 inhibits Flt3, Kit, and Csf1r, thus may have anti-tumor activity in hematological cancers (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CSF1R positive chronic myelomonocytic leukemia predicted - sensitive NMS-P088 Preclinical - Patient cell culture Actionable In a preclinical study, NMS-P088 inhibited proliferation of Csf1r-expressing blasts derived from chronic myelomonocytic leukemia patients (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324). detail...
Clinical Trial Phase Therapies Title Recruitment Status